Asciminib (ABL001)

An allosteric inhibitor of Abl1

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥425.00

340.00

- +
5mg

￥937.00

750.00

- +
10mg

￥1437.00

1150.00

- +
25mg

￥2962.00

2370.00

- +
50mg

￥4612.00

3690.00

- +
100mg

￥7137.00

5710.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Asciminib is an allosteric inhibitor of Abl1 (IC₅₀ = 0.45 nM).¹ It is selective for Abl1 over a panel of more than 60 additional kinases (IC₅₀s = >10 μM), as well as ion channels, nuclear receptors, G protein-coupled receptors (GPCRs), and transporters. Asciminib inhibits the proliferation of Luc-Ba/F3 cells transformed with wild-type Bcr-Abl1 or the drug-resistant mutant Bcr-Abl1^T315I (GI₅₀s = 1 and 25 nM, respectively), as well as other drug-resistant mutants.² It reduces tumor growth in a KCL-22 chronic myelogenous leukemia (CML) mouse xenograft model when administered at a dose of 3 mg/kg twice per day and induces tumor regression at doses of greater than or equal to 7.5 mg/kg twice per day.

1.Wylie, A.A., Schoepfer, J., Jahnke, W., et al.The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Nature543(7647)733-737(2017) 2.Schoepfer, J., Jahnke, W., Berellini, G., et al.Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1J. Med. Chem.61(18)8120-8135(2018)

Protocol

Cell experiment:

Ba/F3 cells are treated with a range concentration of asciminib (0-10000 nM) for 48 h. Cell proliferation is measured using the Britelite luciferase detection assay[1].

Animal experiment:

Mice: Asciminib efficacy in three patient-derived ALL systemic xenograft models (ALL-7015, AL-7119 and AL-7155) is assessed by FACS monitoring of the percentage of CD45+ cells per live cell in blood samples taken at varying time points after dosing with either 7.5 mg/kg BID (group 2) or 30 mg/kg BID (group 3) asciminib for 3 weeks[1].

参考文献:

[1]. Wylie AA, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017 Mar 30;543(7647):733-737.